Mesothelioma is also responsive to immunotherapy which has now entered into standard care (6–11) and there is evidence it may be responsive to Stimulator of Interferon Genes (STING) agonists (12) which is reported to target tumor blood vessels and the immune system. Here, STING1 is linked to neoplasm.